Although these approaches have advantages in terms of simplicity and costs, for complex and heterogeneous diseases, single-molecule biomarkers tend to provide insufficient accuracy and robustness across different patient cohorts (even the widely accepted PSA test for prostate cancer has a limited sensitivity of 72.1% according to a meta-analysis [6]). This evidence concerns the gene KLK3 and prostate carcinoma.